Jackson Square Partners LLC Has $2.95 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Jackson Square Partners LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,996 shares of the medical research company’s stock after selling 746 shares during the period. Jackson Square Partners LLC’s holdings in IQVIA were worth $2,947,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $186.35 on Tuesday. The company’s 50 day simple moving average is $194.58 and its 200 day simple moving average is $207.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.54. The stock has a market capitalization of $32.86 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.